CRESCENT BIOPHARMA, INC. cotiza a 14.46 USD y tiene una capitalización bursátil de $537M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic pa…
| Periodo | 2026-07 | 2026-04 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.62 | $-0.70 | $-4.92 | $-1.37 |
| Estimado | $-0.64 | $-0.95 | $-2.82 | $-1.38 |
| Sorpresa | +3.1% | +26.3% | -74.5% | +0.7% |
| Métrica | CBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1407.5% | -38.6% | -1368.9% |
| Net Margin | -1419.6% | -33.6% | -1386.0% |
| FCF Margin | -668.1% | -13.9% | -654.3% |
| ROE | -75.8% | -40.4% | -35.4% |
| ROA | -64.1% | -32.0% | -32.1% |
| Current Ratio | 6.56 | 2.84 | +3.72 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |